{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:21Z","timestamp":1785822441445,"version":"3.56.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy has significantly improved pathological response rates in resectable non-small cell lung cancer (NSCLC). However, whether it increases surgical complexity compared with upfront surgery followed by adjuvant therapy remains clinically debated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 121 NSCLC patients (81 neoadjuvant; 40 adjuvant) treated between 2021 and 2024. Inverse Probability of Treatment Weighting (IPTW) was applied to adjust for baseline imbalances. Surgical difficulty was quantified using a standardized 10-point scoring system. Multivariable logistic regression was then performed to identify independent risk factors for high-difficulty procedures (score &amp;gt;5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IPTW successfully achieved balance across all baseline covariates. The neoadjuvant group exhibited significantly higher technical complexity than the adjuvant group (39.8% vs. 2.7% high difficulty;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Minimally invasive approach completion was substantially lower in the neoadjuvant group (57.8% vs. 93.5%), with significantly higher conversion rates (33.9% vs. 6.5%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Anatomical challenges, particularly dense hilar adhesions and vascular fibrosis (the \u201cfrozen hilum\u201d), were more prevalent after neoadjuvant treatment (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Multivariable analysis confirmed neoadjuvant therapy as the primary independent driver of increased surgical difficulty (OR: 0.032 for adjuvant vs. neoadjuvant;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Postoperative recovery metrics, including chest tube duration and hospital stay, remained comparable between groups after weighting (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy was associated with greater technical surgical difficulty and higher conversion rates compared with upfront surgery followed by adjuvant therapy. Despite these technical challenges, surgical resection remains safe and feasible, though it requires specialized thoracic expertise to manage complex anatomical alterations effectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fsurg.2026.1881043","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:37:51Z","timestamp":1785821871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Will neoadjuvant chemoimmunotherapy complicate subsequent surgery compared with adjuvant chemoimmunotherapy?"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhoujunyi","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoshuai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenrong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.ctarc.2023.100742","article-title":"Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: a retrospective observational study","volume":"36","author":"Shah","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100384","DOI":"10.1016\/j.jtocrr.2022.100384","article-title":"Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis","volume":"3","author":"Rosner","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100840","DOI":"10.1016\/j.lanepe.2024.100840","article-title":"New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet (London, England)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.esmoop.2022.100494","article-title":"Corrigendum to \u2018long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16\/96, SAKK 16\/00, SAKK 16\/01, and SAKK 16\/08 trials\u2019: [ESMO open volume 7, issue 2, (2022), 100455]","volume":"7","author":"K\u00f6nig","year":"2022","journal-title":"ESMO open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/jco.21.00276","article-title":"SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-A multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/s1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cllc.2023.08.017","article-title":"Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: a systematic review","volume":"24","author":"Takada","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jtho.2024.02.009","article-title":"Neoadjuvant chemoimmunotherapy complicates subsequent surgical resection and adjuvant immunotherapy is preferable from the surgical standpoint","volume":"19","author":"Ugalde Figueroa","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ezaf218","DOI":"10.1093\/ejcts\/ezaf218","article-title":"What is the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC)?: a real-world study","volume":"67","author":"Tian","year":"2025","journal-title":"Eur J Cardiothorac Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.21037\/tlcr-20-778","article-title":"Sleeve lobectomy after neoadjuvant chemoimmunotherapy\/chemotherapy for local advanced non-small cell lung cancer","volume":"10","author":"Liang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.21037\/jtd-21-1195","article-title":"Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer","volume":"13","author":"Xu","year":"2021","journal-title":"J Thorac Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1111\/1759-7714.14127","article-title":"Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer","volume":"12","author":"Hong","year":"2021","journal-title":"Thorac Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.21037\/jtd-21-1007","article-title":"Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study","volume":"13","author":"Zhang","year":"2021","journal-title":"J Thorac Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100308","DOI":"10.1016\/j.jtocrr.2022.100308","article-title":"Real-World perspectives from surgeons and oncologists on resectability definition and multidisciplinary team discussion of stage III NSCLC in people\u2019s republic of China, Hong Kong, and Macau: a physician survey","volume":"3","author":"Lee","year":"2022","journal-title":"JTO Clin Res Rep"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1881043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:37:52Z","timestamp":1785821872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1881043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":24,"alternative-id":["10.3389\/fsurg.2026.1881043"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2026.1881043","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1881043"}}